Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Clinical Trial of RVU120 as Monotherapy and in Combination With Ruxolitinib in Patients With Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)

NCT06397313 is registered in ClinicalTrials.gov with Ryvu Therapeutics SA as lead sponsor.

NCT NCT06397313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06397313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Clinical Trial of RVU120 as Monotherapy and in Combination With Ruxolitinib in Patients With Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)
Lead sponsor
Ryvu Therapeutics SA
Phase
Phase 2
Overall status
Terminated
Start date
September 19, 2024
Completion date
June 30, 2026
Enrollment
36 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis